CONNECT WITH US:
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Nov 20, 2023 16:05 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline.
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
Oct 25, 2023 19:43 JST
Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
Oct 16, 2023 13:07 JST
Eisai Co. Ltd announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference.
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
Oct 11, 2023 12:07 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2023, which is taking place virtually and in-person in Madrid, Spain from October 20 to 24.
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
Oct 04, 2023 18:08 JST
Eisai Co., Ltd. hereby announcesthat the Company has today decided to absorb and merge with KAN Research Institute, Inc., the Company's wholly owned subsidiary on April 1, 2024.
Eisai Launches New "Innovation" Page on Corporate Website
Sep 28, 2023 16:05 JST
Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website.
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
Sep 28, 2023 13:49 JST
Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society.
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
Sep 25, 2023 14:17 JST
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD).
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Sep 21, 2023 11:26 JST
Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia.
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
Sep 12, 2023 18:05 JST
Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai.
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
Aug 04, 2023 12:04 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002.
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 20, 2023 10:23 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes.
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
Jul 12, 2023 09:05 JST
Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD).
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jul 07, 2023 12:21 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
Jun 30, 2023 10:08 JST
Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement.
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City
Jun 22, 2023 16:08 JST
Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo.
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 12, 2023 09:13 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD).
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
Jun 08, 2023 12:32 JST
This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries.
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
Jun 02, 2023 11:20 JST
Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26, 2023 13:15 JST
These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502).
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25, 2023 20:02 JST
Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027.
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24, 2023 17:03 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6.
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 20, 2023 09:20 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 16, 2023 08:27 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
May 08, 2023 10:15 JST
Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
Apr 06, 2023 17:32 JST
Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Eisai's medium-term business plan "EWAY Future & Beyond".
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
Apr 04, 2023 12:23 JST
Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) using simulation modeling was published in the peer-reviewed journal Neurology and Therapy.
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
Apr 03, 2023 12:06 JST
Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system.
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
Mar 31, 2023 15:51 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL).
Mitsubishi Shipbuilding Holds Christening and Handover Ceremony in Shimonoseki for Demonstration Test Ship for Liquefied CO2 Transport
Nov 28, 2023 17:47 JST
Hitachi awarded Sustainable Markets Initiative 2023 Terra Carta Seal
Nov 28, 2023 17:43 JST
MHI Succeeded Combustion Test of Ammonia Single-Fuel Burners
Nov 28, 2023 16:40 JST
JCB partners with FrenchSys to boost card acceptance across France
Nov 28, 2023 12:00 JST
Toyota Launches IMV 0 in Thailand Providing Mobility to Make People's Lives Better through Customizability
Nov 27, 2023 17:30 JST
MHI and Orica Announce Collaboration to Explore Emissions Reduction Opportunities
Nov 27, 2023 15:29 JST
Mitsubishi Motors to Launch the New Minicab EV Electric Commercial Vehicle in Japan in December
Nov 24, 2023 16:32 JST
DOCOMO to Showcase Diverse Technologies at docomo Open House '24
Nov 22, 2023 20:39 JST
Renewal of O&M Services Contract for APM System at Dubai International Terminal 3
Nov 22, 2023 20:21 JST
Hitachi Energy unveils new emission-free alternative to diesel- powered generators
Nov 22, 2023 20:05 JST
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
Nov 22, 2023 09:28 JST
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Nov 20, 2023 17:05 JST
MHI and ITB Advance R&D Collaboration to Explore Zero Carbon Technologies in Indonesia
Nov 20, 2023 12:47 JST
Dream 1-2-3 finish at home for TOYOTA GAZOO Racing
Nov 20, 2023 12:07 JST
Fujitsu to license Topological Data Analysis technology to Delight Health, a Bay Area startup focused on providing innovative mental health solutions
Nov 20, 2023 10:15 JST
Bluelight.inc is Getting Released on the Mainnet
Nov 15, 2023 16:00 JST
Hitachi Energy wins order to upgrade world-record high-voltage direct current transmission system
Nov 10, 2023 15:12 JST
NEC Thailand collaborates with Industrial Estate Authority of Thailand to monitor and manage industrial waste in 14 industrial estates
Nov 10, 2023 12:05 JST
SoftBank Corp. completes nationwide expansion of all optical network in core areas in Japan leveraging Fujitsu's disaggregation-type optical transmission system
Nov 10, 2023 10:43 JST
Global Innovation & Value Summit (GIVS) 2023, Nov 17: 'Moving Forward with ESG: Scoring for Value Creation'
Nov 10, 2023 09:00 JST
More Latest Release >>